Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moMICAFUNGIN SODIUM (micafungin sodium) by Fresenius Kabi is [see microbiology ()] . Approved for acute disseminated candidiasis, abscesses in adult, older [see clinical studies () and 6 more indications. First approved in 2019.
Drug data last refreshed 20h ago
[see Microbiology ()] .
Worked on MICAFUNGIN SODIUM at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo